Engraftment versus immunosuppression: Cost-benefit analysis of immunosuppression after intrahepatic murine islet transplantation

Transplantation

Volumn 97, Issue 10, 2014, Pages 1019-1026

  Marzorati, Simona ^a   Melzi, Raffaella ^a   Citro, Antonio ^a,b   Cantarelli, Elisa ^a   Mercalli, Alessia ^a   Scavini, Marina ^a   Piemonti, Lorenzo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Immunosuppression side effects; Islet transplant; MMF; Rapamycin; Tacrolimus

Indexed keywords

GLUCOSE; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG EFFECT; ENGRAFTMENT; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PORTAL VEIN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ANIMALS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, EXPERIMENTAL; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYCOPHENOLIC ACID; POSTOPERATIVE CARE;

EID: 84901254508     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000104     Document Type: Article

References (30)

1. Barton FB, RickelsMR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999Y2010. Diabetes Care 2012; 35: 1436.
2. Piemonti L, Everly MJ, Maffi P, et al. Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes 2013; 62: 1656.
3. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007; 117: 2553.
4. Soleimanpour SA, Crutchlow MF, Ferrari AM, et al. Calcineurin signaling regulates human islet {beta}-cell survival. J Biol Chem 2010; 285: 40050.
5. Heit JJ, Apelqvist AA, Gu X, et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature 2006; 443: 345.
6. Bell E, Cao X, Moibi JA, et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 2003; 52: 2731.
7. Zahr E, Molano RD, Pileggi A, et al. Rapamycin impairs in vivo proliferation of islet beta-cells. Transplantation 2007; 84: 1576.
8. Niclauss N, Bosco D, Morel P, et al. Rapamycin impairs proliferation of transplanted islet beta cells. Transplantation 2011; 91: 714.
9. Zhang N, Su D, Qu S, et al. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes 2006; 55: 2429.
10. Cantaluppi V, Biancone L, Romanazzi GM, et al. Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation. Am J Transplant 2006; 6: 2601.
11. Mercalli A, Calavita I, Dugnani E, et al. Rapamycin unbalances the polarization of human macrophages to M1. Immunology 2013; 140: 179.
12. Desai NM, Goss JA, Deng S, et al. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity? Transplantation 2003; 76: 1623.
13. Shapiro AM, Gallant HL, Hao EG, et al. The portal immunosuppressive storm: relevance to islet transplantation? Ther Drug Monit 2005; 27: 35.
14. Larsen JL, Bennett RG, Burkman T, et al. Tacrolimus and sirolimus cause insulin resistance in normal sprague dawley rats. Transplantation 2006; 82: 466.
15. Melzi R, Sanvito F, Mercalli A, et al. Intrahepatic islet transplant in the mouse: functional and morphological characterization. Cell Transplant 2008; 17: 1361.
16. Melzi R, Battaglia M, Draghici E, et al. Relevance of hyperglycemia on the timing of functional loss of allogeneic islet transplants: implication for mouse model. Transplantation 2007; 83: 167.
17. Dong M, Parsaik AK, Eberhardt NL, et al. Cellular and physiological mechanisms of new-onset diabetes mellitus after solid organ transplantation. Diabet Med 2012; 29: e1.
18. Johnson JD, Ao Z, Ao P, et al. Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets. Cell Transplant 2009; 18: 833.
19. Bosco D, Armanet M, Morel P, et al. Unique arrangement of alphaand beta-cells in human islets of Langerhans. Diabetes 2010; 59: 1202.
20. Butler PC, Meier JJ, Butler AE, et al. The replication of beta cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab 2007; 3: 758.
21. De Vos A, Heimberg H, Quartier E, et al. Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression. J Clin Invest 1995; 96: 2489.
22. Fiaschi-Taesch N, Bigatel TA, Sicari B, et al. Survey of the human pancreatic beta-cell G1/S proteome reveals a potential therapeutic role for cdk-6 and cyclin D1 in enhancing human beta-cell replication and function in vivo. Diabetes 2009; 58: 882.
23. Eizirik DL, Pipeleers DG, Ling Z, et al. Major species differences between humans and rodents in the susceptibility to pancreatic beta-cell injury. Proc Natl Acad Sci U S A 1994; 91: 9253.
24. Soleimanpour SA, Crutchlow MF, Ferrari AM, et al. Calcineurin signaling regulates human islet {beta}-cell survival. J Biol Chem 2010; 285: 40050.
25. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004; 172: 2731.
26. Cantarelli E, Citro A, Marzorati S, et al. Murine animal models for preclinical islet transplantation: no model fits all (research purposes). Islets 2013; 5: 79.
27. McCall M, Pawlick R, Kin T, et al. Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. Am J Transplant 2012; 12: 322.
28. Citro A, Cantarelli E, Maffi P, et al. CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. J Clin Invest 2012; 122: 3647.
29. Matsumoto S, Takita M, Chaussabel D, et al. Improving efficacy of clinical islet transplantation with iodixanol-based islet purification, thymoglobulin induction, and blockage of IL-1beta and TNF-alpha. Cell Transplant 2011; 20: 1641.
30. Rickels MR, Mueller R, Teff KL, et al. {beta}-Cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants. J Clin Endocrinol Metab 2010; 95: 1238.